MLH1 promoter methylation is more often detected in the early stages and in less aggressive gastric tumors [12–16], whereas MGMT promoter methylation is more typical of late-stage stomach adenocarcinomas and poor prognoses [18, 19]. This evidence concerns the gene MLH1 and gastric adenocarcinoma.